STOCK TITAN
  1. Home
  2. Sec-filings
  3. CDNA
  4. [144] CareDx, Inc. SEC Filing

CDNA (CDNA) insider to sell 44,700 shares valued at $2.10M on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

The filing reports a proposed sale of up to 44,700 shares of CDNA common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, to be effected on or after August 4, 2026 on NASDAQ, with an aggregate market value of $2,103,497.07. The shares are shown as originating from multiple grants of restricted stock vesting under a registered compensation plan, with vesting dates ranging from 2014 through 2026 and described as issued by the issuer as compensation.

Positive

  • None.

Negative

  • None.
Shares proposed for sale 44,700 shares Common stock listed in the securities information section
Aggregate market value $2,103,497.07 Value associated with the 44,700 common shares
Additional share figure listed 51,734,000 shares Appears in the securities information table alongside the proposed sale
Largest single vesting entry 12,500 shares Restricted stock vesting under a registered plan dated 01/01/2014
Example vesting entry 2,963 shares Restricted stock vesting event dated 07/08/2024 marked as Compensation
Planned sale date 08/04/2026 Date associated with the proposed disposition of 44,700 shares
Form 144 regulatory
"144: Filer Information 144: Issuer Information 144: Securities Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Restricted Stock Vesting Under a Registered Plan financial
"Common | 01/05/2022 | Restricted Stock Vesting Under a Registered Plan | Issuer"
Executive Financial Services financial
"Common | Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"
Compensation financial
"12500 | 01/01/2014 | Compensation Common | 07/08/2025 | Restricted Stock Vesting"
Securities To Be Sold regulatory
"144: Securities To Be Sold Common | 01/05/2022 | Restricted Stock Vesting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

How many CDNA shares are proposed to be sold under this Form 144?
The Form 144 indicates a proposed sale of 44,700 shares of CDNA common stock. These shares are to be sold through a designated broker on the NASDAQ market, subject to applicable Rule 144 conditions.

What is the aggregate market value of the CDNA shares covered by this Form 144?
The filing lists an aggregate market value of $2,103,497.07 for the 44,700 CDNA common shares. This figure reflects the value used for Rule 144 reporting, based on the information provided in the securities section.

When is the planned sale date for the CDNA shares in this Form 144?
The securities information specifies a planned sale date of 08/04/2026. This is the date associated with the proposed disposition of the 44,700 CDNA common shares on the NASDAQ market through the named broker.

Which broker is handling the proposed CDNA share sale reported here?
The proposed sale of CDNA common stock is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the executing broker for the transaction.

What is the source of the CDNA shares being sold under this Form 144?
The shares are shown as originating from restricted stock vesting under a registered plan. Multiple vesting entries, each labeled as Compensation, span dates from 2014 through 2026 and indicate issuer-granted restricted stock awards.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR